News
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...
Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...
Zacks Investment Research on MSN2d
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...
The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...
3d
Novo Nordisk's Wegovy Gains U.S. Approval for MASH Treatment: A New Era in Liver Disease Management
In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...
Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted the company accelerated approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback